LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.
Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.
What stood out most at this year's largest urology gathering wasn't just the technology. It was the momentum behind where the specialty is heading.
Across the conference floor, several themes kept surfacing:
- The continued rise of minimally invasive treatment options that prioritize both outcomes and quality of life
- Rapid advancements in robotics and image-guided procedures designed to improve precision and consistency
- Smarter diagnostics powered by genomics, AI, and data-driven decision-making
- Growing adoption of digital health and remote monitoring tools that make care more connected and convenient
- Increased focus on workflow efficiency, patient experience, and reducing barriers to care
What became clear is that innovation in urology is no longer happening in isolated pockets. It's happening across the entire care continuum, from diagnosis to treatment to long-term monitoring. Most importantly, the people behind these innovations remain deeply committed to advancing patient care and pushing the field forward.
Brittany Erickson, MAOM and David Forney break down the biggest trends, conversations, and takeaways from the event in our latest Buzz Report. If you're interested in where urology is headed next, it's worth a watch!
#AUA2026#UrologyInnovation#MedTechInsights
Hey everyone, it's Brittany Erickson and David Forney with Floodgate Medical. We were lucky enough to attend the 121st annual American Urological Association meeting that brought the entire urology world to Washington DC And this year, honestly, what a week. That's right from the second exhibit hall opened, the energy was nonstop. Packed booths, live demos, standing room only conversations. It really felt like urology innovation is accelerating faster than ever. And every year one of our favorite. Parts of a UA's getting to connect with the amazing medtech rock stars across the industry. This includes founders, physicians, engineers, clinical specialists, the commercial teams. Behind the teams, you could feel the passion everywhere. Everyone's focused on the same thing, improving patient care and pushing this industry forward. And this year especially there was a huge focus on less invasive therapy, robotics, AI, diagnostics, digital health, and workflow efficiency. So today we want to highlight a few companies and. Friends that really stood out to us during a UA 2026. So let's start with Biobot Surgical. Biobot definitely generated a lot of buzz this year and their robotic assisted platform focused on precision navigation for minimally invasive prostate interventions. What's exciting about Biobot is their focus on image guided precision, helping physicians perform more targeted procedures with enhanced accuracy. You could really feel the excitement around technologies that help improve prostate cancer targeting while potentially reducing procedural variability. And honestly, robotics overall was one of the hottest conversations throughout the meeting. Every year we're seeing systems become more intelligent, more compact, and more procedure specific. Another company had a lot of attention this year was Bioprotect. Bioprotect. Continues building momentum around their space or technology designed to help protect healthy tissue during prostate radiation therapy. And this fits perfectly into one of the biggest themes we saw a this year. Improving patient outcomes while minimizing treatment related side effects. Potions are increasingly looking for technologies that not only improve procedural precision but also preserve quality of life for patients during and after treatment. And you could tell there's real enthusiasm around technologies that help make prostate cancer treatment safer and more patient friendly. Speaking of patient and friendly innovation, let's talk about BPH because BPH innovation was everywhere at AUAR. Ovarium led this conversation by bringing his fresh, minimally invasive approach to treating BPH with their Pro V system, and there was definitely a lot of conversation around it this year. What makes Pro Verum exciting is the focus on relieving urinary obstruction while also preserving sexual function, which continues to be one of the biggest priorities for both physicians and patients. The market is clearly shifting towards therapies that can deliver symptom relief without the invasiveness, downtime, or side effect profile associated with more traditional procedures. Patients want options, physicians want flexibility, and companies like program or helping expand what treatment can look like moving forward. Another company that's gotten a lot of attention in the BPH space was Zen Flow. Zen Flow Spring System generated a ton of interest this year because of its minimally invasive design approach. What's interesting is how many companies are now approaching. PH from completely different angles. Some are using implants, some are using thermal therapies, others are focused on mechanical reshaping. But the common goal is improving outcomes while making treatment easier on patients. And that was honestly one of the coolest parts about a UA this year, seeing how competitive innovation has become in this category. Britney I absolutely and completely agree. Now let's move into diagnostics and digital health because that was another major theme this year throughout the entire meeting brought euro turned heads and modernizing Euro dynamics with their Glean system, which offers a wireless catheter free approach to bladder pressure testing. Traditional urodynamics can be uncomfortable and inconvenient for patients. So seeing companies rethink the entire testing experience is really exciting and providers seem genuinely interested in technologies that improve patient comfort. While also delivering more natural, potentially more accurate diagnostic data, which ties directly into another company that we want to highlight, Minsa Health. Minsa is bringing digital health and remote patient monitoring into urology diagnostics through their smart uroflowmetry platform. Remote monitoring continues to gain momentum across healthcare overall. And Mince is doing a really great job at creating technology that's both patient friendly and clinically useful. And honestly, patients increasingly expect healthcare to become more convenient and connected companies. You can simplify the patient experience while still delivering strong clinical insights are going to continue gaining traction. Absolutely. Another company that made an impression diagnostic this year was Pacific Edge Diagnostics. Pacific Edge continues generally strong momentum around their CX bladder technology which helps support non invasive bladder cancer detection and monitoring their genomic urine testing. Bladder cancer diagnostics and surveillance remain major challenges in urology. So seeing continued advancement in genomic testing was really exciting and for precision medicine overall was a huge topic throughout USA this year. Physicians wanted smarter tools that help guide clinical decisions while potentially reducing unnecessary procedures and improving efficiency. You could definitely fill the industry moving toward more personalized and data-driven care models. Now let's talk about another category that had a lot of traffic this year. Single use endoscopy companies like Pussin, Dornier, Medtech and Macro Alex had a ton of attention throughout the exhibit hall. Single use Futuroscope technology has evolved dramatically over the last several years. The image quality keeps improving. Ergonomics are improving, and hospitals are continuing to evaluate workflow efficiency and infection prevention benefits. And from a hospital operations standpoint, there's growing interest around reducing reprocessing burdens, improving scope availability, and managing maintenance costs associated with reusable systems. It's become a very competitive category, which is great because competition continues driving innovation. And honestly, you could fill up a minimum all over the conference floor, whether it was robotics, diagnostics, BPH. Therapies, digital health, or disposable technologies. Innovation is happening everywhere in urology right now. But beyond the technology itself, what really makes a UA special is the people. And one thing was extremely clear. The passionate industry is contagious. Every conversation we have, whether it's startups, physicians, investors, or large strategic companies, you could tell people genuinely care about improving patient care and advancing medicine. And that's why we love being part of the space. The innovation is incredible, but the people behind it? Ohh, I'd make this industry so exciting, so exciting. We want to give a huge thank you to everyone who took the time to connect with us throughout the week. We love meeting so many Med tech rockstars and hearing about all the incredible work happening across urology. And with a 2026 officially wrapped up, we'll see you next year in San Diego. Everywhere it prevents everywhere anyway. Everywhere everywhere. More compact and more procedure for shoot companies that can simply ohh. Bladder cancer diagnostics and surveillance remain a major challenges. AutoCAD back dramatically over the last several years. That's how we're all yours. The passion is the industry is conducted from. Or we could be like in San Diego. Like could try to be funny.
Business Unit Manager | MedSurg-CMI | AlphaMed | MBA | BSc Biomedical Engineering
We are proud to announce our new partnership with Biolitec as an official distributor, strengthening our commitment to bringing advanced minimally invasive solutions to the field of #Endourology.
Biolitec is globally recognized for its innovation in medical laser technologies, offering high-performance solutions that support physicians in achieving outstanding clinical outcomes across various specialties.
Among the remarkable technologies now joining our portfolio is the #Leonardo® laser platform, including the renowned “dusting” capabilities for stone management. The Leonardo Duster technology delivers precise and efficient laser lithotripsy, enabling effective stone fragmentation with enhanced procedural control, reduced retropulsion, and optimized outcomes for patients and physicians alike.
I would also like to express my sincere appreciation to the business and training team for the excellent educational and hands-on training support provided in their premises in DHCC. Special thanks to Ahmad Sabbagh, Salin George and Benoy Thomas thought the journey and wish the best for our amazing team, Heba Magdy, Madeleine Dahla under the leadership of Hany Shohdy Aziz Gergis.
Al Khayyat Investments (AKI) - Biolitec#Endourology#MedicalDevices#LaserTechnology#biolitec#HealthcareInnovation#Urology#Partnership#MedicalTechnology
We are proud to announce our new partnership with Biolitec as an official distributor, strengthening our commitment to bringing advanced minimally invasive solutions to the field of #Endourology.
Biolitec is globally recognized for its innovation in medical laser technologies, offering high-performance solutions that support physicians in achieving outstanding clinical outcomes across various specialties.
Among the remarkable technologies now joining our portfolio is the #Leonardo® laser platform, including the renowned “dusting” capabilities for stone management. The Leonardo Duster technology delivers precise and efficient laser lithotripsy, enabling effective stone fragmentation with enhanced procedural control, reduced retropulsion, and optimized outcomes for patients and physicians alike.
I would also like to express my sincere appreciation to the business and training team for the excellent educational and hands-on training support provided in their premises in DHCC. Special thanks to Ahmad Sabbagh, Salin George and Benoy Thomas thought the journey and wish the best for our amazing team, Heba Magdy, Madeleine Dahla under the leadership of Hany Shohdy Aziz Gergis.
Al Khayyat Investments (AKI) - Biolitec#Endourology#MedicalDevices#LaserTechnology#biolitec#HealthcareInnovation#Urology#Partnership#MedicalTechnology
🇮🇳 One of the highlights of my recent trip to India was the opportunity to visit several private and government hospitals and gain first-hand insights into one of the world's most dynamic healthcare systems.
A particular honor was being invited as the only European speaker at the conference "Clinical Applications of AI in Radiology" at Max Super Speciality Hospital, Saket, New Delhi—one of India's leading tertiary care centers. There, I had the opportunity to present on Automated Brain MRI Quantification for the Assessment of Neurological Disorders.
What stood out most during the discussions was the shared commitment to improving diagnostic accuracy, efficiency, and patient outcomes through innovation. While healthcare systems differ across regions, India's enormous patient volumes create an especially strong demand for digitalization and scalable AI solutions.
Thank you to the organizers and attendees for the engaging discussions, warm hospitality, and valuable exchange of perspectives. Experiences like these highlight the importance of international collaboration in advancing the future of healthcare.
#MedicalAffairs#HealthcareInnovation#ArtificialIntelligence#Radiology#Neurology#DigitalHealth#MedicalImaging#Neuroradiology#GlobalHealth
I remember when I first met with Dr. Prince in 2021 to talk about my clinical immersion project. He made a compelling argument for research in medical imaging:
"In the early days of blood tests, we could only tell patients if their red blood cells are high, if their platelets are high or low, and if they have a lot of white blood cells. As technology went on, we could report precise numbers for sodium levels, antibodies, and anything else you can think of to compare with baselines. The information was always there!
Right now, medical imaging is in its own infancy. We radiologists only report if the spleen is big (splenomegaly) or not. I want to report the volume of not just the spleen, but of every organ in the abdomen and compare it to a volumetric baseline. The information is there."
Nearly five years later, that idea has still stuck with me. This work is, in a way, a full circle to that conversation. It's humbling to have the Journal of Clinical Medicine (JCM) MDPI spotlight this paper.
The caveat is that organ volume measurements require a segmentation. This work, along with many others, use deep neural networks to hasten the segmentation process. If you are interested in how organ volume measurements give more precise tracking and treatment evaluation, feel free to give this a read!
#Article
Model-Assisted Spleen Contouring for Assessing Splenomegaly in Myelofibrosis: A Fast and Reproducible Approach to Evaluate Progression and Treatment Response
Congratulations to the authors: Arman Sharbatdaran, Téa Cohen, Hreedi Dev, Usama Sattar, Vahid Bazojoo, Yin Wang, Zhongxiu Hu, Chenglin Zhu, Xinzi He, Dominick Romano, Joseph Scandura and Martin R. Prince
🏛️ Affiliations:
• Weill Cornell Medicine, New York, USA
• Department of Radiology, Columbia University, USA
🚀 Why it matters:
Accurate spleen volume measurement is essential for monitoring disease progression and treatment response in myelofibrosis. This study demonstrates that model-assisted (AI-based) contouring provides faster, more reproducible, and more reliable measurements compared to traditional ellipsoidal estimation, with performance comparable to manual contouring but significantly reduced operator time. These findings support the integration of AI tools in clinical workflows and clinical trials for improved decision-making.
Read the full article: https://brnw.ch/21x2gAe#Radiology#Hematology#AIinMedicine#ClinicalResearch#MedicalImaging#Myelofibrosis
The genesis of innovation always comes from a question.
For Mario Romero-Ortega and David N Constantine, that question became a journey, one built on trust, curiosity, persistence, and a belief that selective neuromodulation could fundamentally change the future of pelvic health care. What began as an idea eventually evolved into years of research & development, scientific and technical breakthroughs, and the clinical solution that Juniper Biomedical has developed.
This week at the American Urological Association Annual Meeting in Washington, D.C., Mario, recently welcomed as a senior member of the national academy of inventors (https://lnkd.in/geKMh98e), will present “Our Journey to the Neuromod Prize.” Mario will share the story behind the science, the challenges, and the people who helped move their founding vision forward. The presentation reflects on the path from early discovery through catalysts like the NIH SPARC Neuromod Prize and MedTech Innovator, that accelerated Juniper Biomedical’s groundbreaking work in precision neuromodulation, to today, as we sprint toward our next clinical pilot study.
Read more about Juniper Biomedical’s Neuromod Prize Phase 3 award here:
https://lnkd.in/gCyxgT2K
Joining Mario at AUA will be Co-Founder & CEO David N Constantine and Chief Medical Officer, Jessica D., where the team connects with others shaping the future of urology, pelvic health, and neuromodulation.
#AUA2026#Neuromodulation#PelvicHealth#MedicalInnovation#MedTech#Urology
For decades, urinary catheter innovation has largely focused on coatings, materials, and incremental changes - while many of the underlying clinical challenges remain unresolved.
At AUA Innovation Nexus 2026 in Washington, D.C., Nowwell CEO & CMO Nikolai Hoffmann-Petersen, MD, presented Nowwell’s approach to rethinking the Foley catheter, introducing the NowCath Foley catheter and the upcoming REDUCE Trial - a randomized, blinded crossover study in long-term catheterized patients.
Long-term catheterization continues to impact both patients and healthcare systems through catheter-associated urinary tract infections, blockages, residual urine, and avoidable complications.
At Nowwell, our purpose is enhancing dignity and quality of life for people affected by urinary incontinence and retention.
We are grateful to the AUA Innovation Nexus team, our Advisory Board, collaborators, and supporters for being part of this journey.
Dean Elterman, MD, MSc, FRCSCSteven Kaplan
Anne L. Ackerman
Jennifer Anger, MD, MPH
Marcus Drake
#AUA2026#AUA#AUAInnovationNexus#MedTech#Innovation#Urology#ClinicalTrials
Where can we make meaningful changes for our patients? Take urinary catheters - no significant changes in decades but much can be improved. Nowwell is taking on the challenge with great leadership and advisory teams. #AUA26
For decades, urinary catheter innovation has largely focused on coatings, materials, and incremental changes - while many of the underlying clinical challenges remain unresolved.
At AUA Innovation Nexus 2026 in Washington, D.C., Nowwell CEO & CMO Nikolai Hoffmann-Petersen, MD, presented Nowwell’s approach to rethinking the Foley catheter, introducing the NowCath Foley catheter and the upcoming REDUCE Trial - a randomized, blinded crossover study in long-term catheterized patients.
Long-term catheterization continues to impact both patients and healthcare systems through catheter-associated urinary tract infections, blockages, residual urine, and avoidable complications.
At Nowwell, our purpose is enhancing dignity and quality of life for people affected by urinary incontinence and retention.
We are grateful to the AUA Innovation Nexus team, our Advisory Board, collaborators, and supporters for being part of this journey.
Dean Elterman, MD, MSc, FRCSCSteven Kaplan
Anne L. Ackerman
Jennifer Anger, MD, MPH
Marcus Drake
#AUA2026#AUA#AUAInnovationNexus#MedTech#Innovation#Urology#ClinicalTrials
Such an incredible opportunity, thank you, FloodGate Medical for allowing me to attend and learn so much about the industry we specifically focus on.